Are you Dr. Kurtoglu?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 34 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
10 Center Dr
Bldg 10 Room 12n226
Bethesda, MD 20892Phone+1 301-496-4916
Summary
- Dr. Metin Kurtoglu, MD is an internist in Bethesda, Maryland. He is currently licensed to practice medicine in District of Columbia and Florida.
Education & Training
- National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2013 - 2016
- University of Miami/Jackson Health SystemResidency, Internal Medicine, 2010 - 2013
- Istanbul University FomClass of 2002
Certifications & Licensure
- DC State Medical License 2013 - 2014
- FL State Medical License Active through 2014
Clinical Trials
- Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma Start of enrollment: 2018 Feb 26
Publications & Presentations
PubMed
- 58 citationsPreclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma.Liang Lin, Shih-Feng Cho, Lijie Xing, Kenneth Wen, Yuyin Li
Leukemia. 2021-03-01 - 38 citationsGlobal variability of the human IgG glycome.Jerko Štambuk, Natali Nakić, Frano Vučković, Maja Pučić-Baković, Genadij Razdorov
Aging. 2020-08-12 - 6 citationsEngineering human stellate cells for beta cell replacement therapy promotes in vivo recruitment of regulatory T cells.Dilem Ceren Oran, Tolga Lokumcu, Yasemin Inceoglu, Mukrime Birgul Akolpoglu, O. Albayrak
Materials Today. Bio. 2019-03-01
Press Mentions
- Maryland Stem Cell Research Commission Announces over $6 Million in Awards to Accelerate CuresMay 9th, 2021
- A More Targeted CAR-T Cell-Based Therapy for Myasthenia Gravis Moves into Clinical Trial with University of FloridaNovember 7th, 2019
- Cartesian Initiates CAR-T Clinical Trial in Myasthenia GravisNovember 5th, 2019